FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 775 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with... March 3, 2026 Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in... April 8, 2022 EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the... February 19, 2021 Adding Pembrolizumab to Standard Chemotherapy, Followed by Pembrolizumab Maintenance, Results in... March 30, 2023 Load more HOT NEWS With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... Coming Soon: Medicare Drug Price Negotiations EMA Recommends Extension of Indications for Idecabtagene Vicleucel
